- Home
- CMCL vs PBYI Comparison
CMCL vs PBYI Comparison
Compare CMCL & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMCL | PBYI |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.3M | 364.9M |
| IPO Year | 2003 | 2011 |
Fundamental Metrics
Financial Performance| Metric | CMCL | PBYI |
|---|---|---|
| Price | $19.62 | $7.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | ★ 237.7K | 229.9K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | $38.54 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.45 | $3.03 |
| 52 Week High | $38.75 | $8.41 |
Technical Indicators
Market Signals| Indicator | CMCL | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 62.32 |
| Support Level | $18.45 | $6.93 |
| Resistance Level | $21.80 | N/A |
| Average True Range (ATR) | 0.86 | 0.36 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 35.67 | 67.39 |
Price Performance
Historical ComparisonAbout CMCL Caledonia Mining Corporation Plc
Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. Its project includes Maligreen and Motapa.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.